Fig. 2

ELiA-TRAb levels in the different groups enrolled in the study. u-GD, Graves’ disease before the treatment, t-GD GD on treatment, GD/GO Graves’ patients with orbitopathy, NTMG multinodular non-toxic goiter, TA/TMG toxic adenoma/toxic multinodular goiter, HT Hashimoto’s thyroiditis; NTAD non-thyroid autoimmune diseases, NC normal controls, % positive cases, c.o cut-off